Press Release
Stockholm November 17, 2026

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE.

Subscription period in Xspray Pharma's rights issue starts today

The subscription period in Xspray Pharma AB's (publ) rights issue, announced on 6 November, starts today. The subscription period runs up to and including 1 December 2026. Trading in subscription rights runs from today up to and including 26 November.

Shareholders who held shares in Xspray Pharma on the record date of 13 November have received one subscription right for each share held. Five subscription rights entitle the holder to subscribe for one new share at SEK 9.50 during the subscription period.

The subscription period runs up to and including 1 December, but banks and securities institutions may apply earlier deadlines for subscribing for shares. Shareholders therefore need to check the deadlines applied by their bank or securities institution.

Those who do not wish to exercise their subscription rights to subscribe for new shares may instead sell them during the trading period. To avoid losing the value of the subscription rights, holders need either to exercise them or sell them within the respective deadlines. Unexercised subscription rights expire without value and without compensation to the holder.

Full information about the rights issue is available on Xspray Pharma's website under Rights Issue November 2026.

For further information, please contact:

Jacob Nyberg, IRO
Xspray Pharma AB (publ)
Tel: + 46 (0) 70 767 08 83
E-mail: ir@xspray.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development utilizing its innovative, patent protected HyNap™ technology platform to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology market segment, often with high drug prices. The company's goal is to become the market leader in improved PKI's for cancer treatment. Xspray Pharma's lead drug candidate, Dasynoc® and Nilopki® (an optimized version of Tasigna®) are currently undergoing FDA review. Dasynoc is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose due to a better solubility profile. Its compatibility with proton pump inhibitors (PPIs), which are often co-prescribed to patients with CML and ALL, is a significant advantage. Xspray Pharma is building a robust product portfolio, including Nilopki and XS008-axitinib (an optimized version of Inlyta®) and XS025-cabozantinib (an optimized version of Cabometyx®).

The Xspray Pharma AB-share is trading at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). www.xspraypharma.com.

Attachments

Subscription period in Xspray Pharma's rights issue starts today